American Thyroid Association Policy Statement: Impact of Changes in Fine Needle Aspiration Biopsy Reimbursement on Clinical Care of Patients with Thyroid Nodules in the United States.
Leslie S Eldeiry, Jennifer E Lawrence, Charit Taneja, Debra Margulies
{"title":"American Thyroid Association Policy Statement: Impact of Changes in Fine Needle Aspiration Biopsy Reimbursement on Clinical Care of Patients with Thyroid Nodules in the United States.","authors":"Leslie S Eldeiry, Jennifer E Lawrence, Charit Taneja, Debra Margulies","doi":"10.1089/thy.2024.0442","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> The Clinical Affairs Committee of the American Thyroid Association has developed this statement to describe recent changes in the billing and coding of ultrasound-guided fine needle aspiration procedures of thyroid nodules, and to raise awareness of the adverse consequences that have arisen as a result. <b><i>Review:</i></b> A reduction in payment of ultrasound-guided fine needle aspiration procedures was enacted by the Centers for Medicare and Medicaid Services in 2019. The Clinical Affairs Committee has sought to examine the effects of the change in reimbursement on the care of patients with thyroid diseases. <b><i>Summary:</i></b> The historical background of the changes in payment structure for ultrasound-guided fine needle aspiration of thyroid nodules is discussed. The years 2019 and 2020 saw a significant decline in claims for ultrasound-guided fine needle aspiration procedures, concomitant with a shift in the performance of these procedures away from non-facility outpatient settings and a rise in costs to the health care system. <b><i>Conclusion:</i></b> Several negative consequences of the decrease in reimbursement for ultrasound-guided fine needle aspiration of thyroid nodules have arisen. This has led to significant concern among clinicians who care for patients with thyroid diseases regarding delays in patient access to care and diagnosis, and a diminished pool of qualified thyroid specialists to perform these procedures in the future.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"1319-1323"},"PeriodicalIF":5.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1089/thy.2024.0442","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The Clinical Affairs Committee of the American Thyroid Association has developed this statement to describe recent changes in the billing and coding of ultrasound-guided fine needle aspiration procedures of thyroid nodules, and to raise awareness of the adverse consequences that have arisen as a result. Review: A reduction in payment of ultrasound-guided fine needle aspiration procedures was enacted by the Centers for Medicare and Medicaid Services in 2019. The Clinical Affairs Committee has sought to examine the effects of the change in reimbursement on the care of patients with thyroid diseases. Summary: The historical background of the changes in payment structure for ultrasound-guided fine needle aspiration of thyroid nodules is discussed. The years 2019 and 2020 saw a significant decline in claims for ultrasound-guided fine needle aspiration procedures, concomitant with a shift in the performance of these procedures away from non-facility outpatient settings and a rise in costs to the health care system. Conclusion: Several negative consequences of the decrease in reimbursement for ultrasound-guided fine needle aspiration of thyroid nodules have arisen. This has led to significant concern among clinicians who care for patients with thyroid diseases regarding delays in patient access to care and diagnosis, and a diminished pool of qualified thyroid specialists to perform these procedures in the future.
导言:美国甲状腺协会临床事务委员会制定了本声明,旨在介绍甲状腺结节超声引导下细针穿刺术的计费和编码方面的最新变化,并提高人们对由此产生的不良后果的认识。回顾:2019 年,美国医疗保险和医疗补助服务中心(Centers for Medicare and Medicaid Services)决定减少超声引导下细针穿刺术的费用。临床事务委员会试图研究报销变化对甲状腺疾病患者护理的影响。摘要:讨论了甲状腺结节超声引导细针穿刺术支付结构变化的历史背景。2019 年和 2020 年,超声引导下细针穿刺术的报销额度大幅下降,与此同时,这些手术的实施也从非设施门诊环境中转移出来,医疗系统的成本也随之上升。结论甲状腺结节超声引导下细针穿刺术的报销额度下降带来了一些负面影响。这引起了甲状腺疾病患者的临床医生的极大关注,他们担心患者在接受治疗和诊断时会出现延误,而且未来能够执行这些手术的合格甲状腺专科医生也会减少。
期刊介绍:
This authoritative journal program, including the monthly flagship journal Thyroid, Clinical Thyroidology® (monthly), and VideoEndocrinology™ (quarterly), delivers in-depth coverage on topics from clinical application and primary care, to the latest advances in diagnostic imaging and surgical techniques and technologies, designed to optimize patient care and outcomes.
Thyroid is the leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. The Journal delivers the latest findings on topics from primary care to clinical application, and is the exclusive source for the authoritative and updated American Thyroid Association (ATA) Guidelines for Managing Thyroid Disease.